Document:

Form of Common Stock Bridge Financing Warrant

 Exhibit 4.5 
 FORM OF COMMON STOCK WARRANT 
 THIS WARRANT AND THE
SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO
ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE SECURITIES ACT, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS. 
  

			
		  	Warrant to Purchase Shares of
	No. CS-[    ]	  	Common Stock

 WARRANT TO PURCHASE 
 COMMON STOCK 
 OF 
 BG MEDICINE, INC. 
 (A DELAWARE CORPORATION) 
 BG Medicine, Inc., a Delaware corporation (the “Company”), for value
received, hereby certifies that              or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company,
at any time before 5:00 p.m., EST, on [10 years from Issue Date] (the “Expiration Date”), the amount of Common Stock, par value $0.001 per share (the “Common Stock”), determined pursuant to
Section 1 herein at a purchase price per share determined pursuant to Section 2 herein. 
 This Warrant is issued
pursuant to that certain Securities Purchase Agreement dated as of September 1, 2005 between the Company and the Purchasers (as defined therein) (the “Purchase Agreement”), and is entitled to the benefits of the Purchase
Agreement. The terms of all warrants issued pursuant to the Purchase Agreement (including this Warrant) are and will be identical except as to the name of the holder thereof, the amount of Common Stock to be purchased by such holder and the date of
issuance thereof. Except as to those terms otherwise defined in this Warrant, all capitalized terms used in this Warrant shall have the respective meanings ascribed to them in the Purchase Agreement. 
 1. Number of Shares for Which Warrant is Exercisable.
 1.1 Upon the consummation of a Qualified Financing prior to the Due Date, the Warrant shall be exercisable for the
number of shares of Common Stock determined by dividing (A) the original principal amount of the Note held by the Holder by (B) the price per share paid by the investors for the class and series of equity securities issued and sold in the
Qualified Financing, as adjusted pursuant to the terms of Section 4 herein, and then multiplying the quotient obtained thereby by thirty percent (30%). 
 1.2 Notwithstanding anything contained herein to the contrary, if for any reason a Qualified Financing is not
consummated prior to the Due Date, the Warrant may, at the sole discretion of the Holder, be exercisable for the number of shares of Common Stock determined (i) pursuant to Section 1.1 above if and when a Qualified Financing is
consummated, or (ii) by dividing (A) the then outstanding principal balance of the Note held by such Holder, by (B) $1.50, as adjusted pursuant to the terms of Section 4 herein, and then multiplying the quotient obtained thereby
by thirty percent (30%). 

 1.3 Notwithstanding anything contained herein to the contrary, upon the
consummation of a Liquidation Event prior to the consummation of a Qualified Financing, the Warrant may, at the sole discretion of the Holder, be exercisable for the number of shares of Common Stock determined (i) pursuant to Section 1.1
above if and when a Qualified Financing is consummated, or (ii) by dividing (A) the then outstanding principal balance of the Note held by such Holder, by (B) $1.50, as adjusted pursuant to the terms of Section 4 herein, and then
multiplying the quotient obtained thereby by thirty percent (30%). 
 2. The Exercise Price. The price per
share of Common Stock at which this Warrant may be exercised (the “Exercise Price”) shall be $0.01. 
 3. Exercise.
 3.1 Manner of Exercise; Payment in Cash. This Warrant may be
exercised by the Holder, in whole or in part, by surrendering this Warrant, with the purchase form appended hereto as Exhibit A duly executed by the Holder, at the principal office of the Company, or at such other place as the Company
may designate, accompanied by payment in full of the Exercise Price payable in respect of the number of shares of Common Stock purchased upon such exercise. Payment of the Exercise Price shall be in cash or by certified or official bank check
payable to the order of the Company. 
 3.2 Effectiveness. Each exercise of this Warrant shall
be deemed to have been effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 3.1 above. At such time, the person or persons in whose name or names
any certificates for Common Stock (or other securities to be issued hereunder) shall be issuable upon such exercise as provided in Section 3.3 below shall be deemed to have become the holder or holders of record of the Common Stock represented
by such certificates. 
 3.3. Delivery of Certificates. As soon as practicable after the
exercise of this Warrant in full or in part, and in any event within ten business days thereafter, the Company at its sole expense will cause to be issued in the name of, and delivered to, the Holder, or, subject to the terms and conditions hereof,
as such Holder may direct: 
 (a) A certificate or certificates for the number of full shares of Common
Stock to which such Holder shall be entitled upon such exercise plus, in lieu of any fractional share to which such Holder would otherwise be entitled, cash in an amount determined pursuant to Section 3.4 hereof, and 
 (b) In case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in
the aggregate on the face or faces thereof for the number of shares of Common Stock (without giving effect to any adjustment therein) equal to the number of such shares called for on the face of this Warrant minus the number of such shares purchased
by the Holder upon such exercise as provided in Section 3.1 above. 
 3.4. Fractional
Shares. The Company shall not be required upon the exercise of this Warrant to issue any fractional shares, but shall make an adjustment therefor in cash on the basis of the fair market value of the Common Stock determined pursuant to
Section 3.5(c) herein. 
 3.5 Right to Convert Warrant into Stock: Net Issuance.
 (a) Right to Convert. In addition to and without limiting the rights of the Holder under the terms of this
Warrant, the Holder shall have the right to convert this Warrant or any portion

  

 2 

 
thereof (the “Conversion Right”) into shares of Common Stock as provided in this Section 3.5. Upon exercise of the Conversion Right with respect to a particular number of
shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the Holder (without payment by the Holder of any Exercise Price or any cash or other consideration) that number of shares of fully paid
and nonassessable Common Stock equal to the quotient obtained by dividing (X) the value of this Warrant (or the specified portion hereof) on the Conversion Date (as defined in subsection (b) hereof), which value shall be determined by
subtracting (A) the aggregate Exercise Price of the Converted Warrant Shares immediately prior to the exercise of the Conversion Right from (B) the aggregate fair market value of the Converted Warrant Shares issuable upon exercise of this
Warrant (or the specified portion hereof) on the Conversion Date by (Y) the fair market value of one share of Common Stock on the Conversion Date. 
 Expressed as a formula, such conversion shall be computed as follows: 
  

							
	N	  	=	  	 B-A
	  	 
		  		  	Y	  	

  

							
	 where:    
	  	N	  	=	  	 the number of shares of Common Stock that may be issued to Holder

				
		  	Y	  	=	  	 the fair market value (FMV) of one share of Common Stock

				
		  	A	  	=	  	 the aggregate Warrant Price (Converted Warrant Shares × Exercise Price)

				
		  	B	  	=	  	 the aggregate FMV (i.e., FMV × Converted Warrant Shares)

 No fractional shares shall be issuable upon exercise of the Conversion
Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the Holder an amount in cash equal to the fair market value of the resulting fractional share
of the Conversion Date. 
 (b) Method of Exercise. The Conversion Right may be exercised by the
Holder by the surrender of this Warrant at the principal office of the Company together with the Subscription Form in the form attached hereto duly completed and executed and indicating the number of shares subject to this Warrant which are being
surrendered (referred to in Section 3.5(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written
statement, or on such later date as is specified therein (the “Conversion Date”), and, at the election of the Holder hereof, may be made contingent upon the occurrence of any of the events specified in Section 4. Certificates
for the shares issuable upon exercise of the Conversion Right and, if applicable, a new Warrant evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the Holder
within 30 days following the Conversion Date. 
 (c) Determination of Fair Market
Value. For purposes of this Section 3.5, “fair market value” of a share of Common Stock as of a particular date (the “Determination Date”) shall mean: 
 (i) If the Conversion Right is exercised in connection with and contingent upon a public offering, and if the
Company’s Registration Statement relating to such public offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the
final prospectus with respect to such offering. 
  

 3 

 (ii) If the Conversion Right is not exercised in connection with and
contingent upon a public offering, then as follows: 
 (1) If traded on a securities exchange, the fair market
value of the Common Stock shall be deemed to be the average of the closing prices of the Common Stock on such exchange over the five-day period ending one Business Day prior to the Determination Date or, if less, such number of days as the Common
Stock has been traded on such exchange; 
 (2) If traded over-the-counter, the fair market value of the Common
Stock shall be deemed to be the average of the closing bid prices of the Common Stock over the five-day period ending one Business Day prior to the Determination Date or, if less, such number of days as the Common Stock has been traded
over-the-counter; and 
 (3) If there is no public market for the Common Stock, then fair market value shall be
determined in good faith by the Board of Directors of the Company. 
 4. Certain Adjustments.
 4.1 Changes in Common Stock. If the Company shall (i) combine the outstanding shares of Common Stock
into a lesser number of shares, (ii) subdivide the outstanding shares of Common Stock into a greater number of shares, or (iii) issue additional shares of Common Stock as a dividend or other distribution with respect to the Common Stock,
the number of shares of Common Stock to be issued pursuant to the terms of the Warrant shall be equal to the number of shares which the Holder would have been entitled to receive after the happening of any of the events described above if such
shares had been issued immediately prior to the happening of such event, such adjustment to become effective concurrently with the effectiveness of such event. The Exercise Price in effect immediately prior to any such combination of Common Stock
shall, upon the effectiveness of such combination, be proportionately increased. The Exercise Price in effect immediately prior to any such subdivision of Common Stock or at the record date of such dividend shall upon the effectiveness of such
subdivision or immediately after the record date of such dividend be proportionately reduced. 
 4.2 Reorganizations and Reclassifications. If there shall occur any capital reorganization or reclassification of the Common Stock (other than a change in par value or a subdivision or combination as provided for in
Section 4.1), then, as part of any such reorganization or reclassification, lawful provision shall be made so that the Holder shall have the right thereafter to receive upon the exercise hereof the kind and amount of shares of stock or other
securities or property which such Holder would have been entitled to receive if, immediately prior to any such reorganization or reclassification, such Holder had held the number of shares of Common Stock which were then purchasable upon the
exercise of this Warrant. In any such case, appropriate adjustment (as reasonably determined by the Board of Directors of the Company) shall be made in the application of the provisions set forth herein with respect to the rights and interests
thereafter of the Holder such that the provisions set forth in this Section 4 (including provisions with respect to adjustment of the Exercise Price) shall thereafter be applicable, as nearly as is reasonably practicable, in relation to any
shares of stock or other securities or property thereafter deliverable upon the exercise of this Warrant. 
 4.3 Merger, Consolidation or Sale of Assets. Subject to the provisions of this Section 4, if there shall be a merger or consolidation of the Company with or into another corporation (other than a merger or
reorganization involving only a change in the state of incorporation of the Company or the acquisition by the Company of other businesses where the Company survives as a going concern), or the sale of all or substantially all of the Company’s
capital stock or assets to any other person, then as a part of such transaction, provision shall be made so that the Holder shall

  

 4 

 
thereafter be entitled to receive the number of shares of stock or other securities or property of the Company, or of the successor corporation resulting from the merger, consolidation or sale,
to which the Holder would have been entitled if the Holder had exercised its rights pursuant to the Warrant immediately prior thereto. In any such case, appropriate adjustment shall be made in the application of the provisions of this Section 4
to the end that the provisions of this Section 4 shall be applicable after that event in as nearly equivalent a manner as may be practicable. 
 4.4 Statement of Adjustment. Whenever the Exercise Price or the Common Stock to be issued hereunder shall be adjusted as provided in this Section 4, the Company shall forthwith file
with the Secretary of the Company or at such other place as shall be designated by the Company, a statement, signed by its chief financial officer, showing in detail the facts requiring such adjustment, the Exercise Price in effect before and after
such adjustment and the kind and amount of shares of capital stock, securities or other property thereafter to be received upon the exercise of this Warrant. The Company shall also cause a copy of such statement to be sent in the manner specified in
Section 8.02 of the Purchase Agreement to the Holder. Where appropriate, such copy may be given in advance and may be included as part of a notice required to be mailed under the provisions of Section 4.5. 
 4.5 Notice of Adjustment. In the event the Company shall propose to take any action of the types described
in Sections 4.1, 4.2 or 4.3, the Company shall give notice to the Holder in the manner set forth in Section 8.02 of the Purchase Agreement, which notice shall specify the record date, if any, with respect to any such action and the date on
which such action is to take place. Such notice shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such action (to the extent such effect may be known at the date of such notice) on the
Exercise Price and the number, kind or class of shares or other securities or property which shall be deliverable or purchasable upon the occurrence of such action or deliverable upon the exercise hereof. In the case of any action which would
require the fixing of a record date, such notice shall be given at least ten days prior to the date so fixed, and in case of all other actions, such notice shall be given at least 20 days prior to the taking of such proposed action. 

4.6 Taxes. The Company shall pay all documentary, stamp or other transactional taxes, but excluding any
income or withholding taxes, attributable to the issuance or delivery of shares of capital stock of the Company upon the exercise or conversion of this Warrant. 
 5. Reservation of Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the exercise of this Warrant, such shares of Common Stock and
other stock, securities and property, as from time to time shall be issuable upon the exercise of this Warrant. The Company covenants that all shares of Common Stock so issuable will, when issued, be duly and validly issued and fully paid and
nonassessable. 
 6. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company, or (in
the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
 7. Transferability. Subject to compliance with applicable federal and state securities laws, this Warrant and all rights hereunder are transferable in whole or in part by the Holder to
any person or entity upon written notice to the Company. The transfer shall be recorded on the books of the Company upon the surrender of this Warrant, properly endorsed, to the Company at its principal offices, and the payment to the Company of all
transfer taxes and other governmental charges imposed on such transfer. In the event of a partial transfer, the Company shall issue to the holders one or more appropriate new warrants. 
  

 5 

 8. No Impairment. The Company will not, by amendment of its Second Amended
and Restated Certificate of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, or any other similar voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Warrant against impairment due to
such event. Without limiting the generality of the foregoing, the Company (a) will not increase the value assigned to any shares of stock receivable on the exercise of the Warrant above the amount payable therefor on such exercise,
(b) will take all action that may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of stock, free from all taxes, liens and charges with respect to the issue thereof, on the
exercise of all of the Warrants from time to time outstanding, and (c) will not consolidate with or merge into any other person or permit any such person to consolidate with or merge into the Company (if the Company is not the surviving
person), unless such other person shall expressly assume in writing and will be bound by all the terms of this Warrant. 
 9. Notices. All notices, requests and other communications hereunder shall be made pursuant to the provisions of Section 9.04 of the Purchase Agreement. 
 10. Waivers and Modifications. Any term or provision of this Warrant may be amended, modified or waived with the written
consent of the Company and the Purchasers holding Warrants with at least 75% of the amounts then outstanding under all of the Warrants. 
 11. Headings. The headings in this Warrant are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions of this
Warrant. 
 12. Governing Law. This Warrant will be governed by and construed in accordance with and governed
by the laws of State of Delaware, without giving effect to the conflict of law principles thereof. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] 
  

 6 

 IN WITNESS WHEREOF, BG Medicine, Inc. caused this Warrant to be executed by an officer
thereunto duly authorized. 
  

			
	BG MEDICINE, INC.
		
	By:	 	 
		 	Name: Pieter Muntendam, M.D.
		 	Title: President

  

 7 

 EXHIBIT A 
 PURCHASE FORM 
 To: BG MEDICINE, INC. 
 The undersigned pursuant to the provisions set forth in the attached Warrant
(No. W-         ), hereby irrevocably elects to (check one): 
  

	 	 ̈	(A) purchase              shares of the Common Stock, par value $0.001 per share, of BG
Medicine, Inc. (the “Common Stock”), covered by such Warrant and herewith makes payment of $            , representing the full purchase price for such
shares at the price per share provided for in such Warrant; or 

  

	 	 ̈	(B) convert              Converted Warrant Shares into that number of shares of fully paid and
nonassessable shares of Common Stock, determined pursuant to the provisions of Section 3.5 of the Warrant. 

 The Common
Stock for which the Warrant may be exercised or converted shall be known herein as the “Warrant Stock”. 
 The
undersigned is aware that the Warrant Stock has not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws. The undersigned understands that reliance by the
Company on exemptions under the Securities Act is predicated in part upon the truth and accuracy of the statements of the undersigned in this Purchase Form. 
 The undersigned represents and warrants that (1) it has been furnished with all information which it deems necessary to evaluate the merits and risks of the purchase of the Warrant Stock, (2) it
has had the opportunity to ask questions concerning the Warrant Stock and the Company and all questions posed have been answered to its satisfaction, (3) it has been given the opportunity to obtain any additional information it deems necessary
to verify the accuracy of any information obtained concerning the Warrant Stock and the Company and (4) it has such knowledge and experience in financial and business matters that it is able to evaluate the merits and risks of purchasing the
Warrant Stock and to make an informed investment decision relating thereto. 
 The undersigned hereby represents and warrant
that it is purchasing the Warrant Stock for its own account for investment and not with a view to the sale or distribution of all or any part of the Warrant Stock. 
 The undersigned understands that because the Warrant Stock has not been registered under the Securities Act, it must continue to bear the economic risk of the investment for an indefinite period of time
and the Warrant Stock cannot be sold unless it is subsequently registered under applicable federal and state securities laws or an exemption from such registration is available. 
 The undersigned agrees that it will in no event sell or distribute or otherwise dispose of all or any part of the Warrant Stock unless
(1) there is an effective registration statement under the Securities Act and applicable state securities laws covering any such transaction involving the Warrant Stock, or (2) the Company receives an opinion satisfactory to the Company of
the undersigned’s legal counsel stating that such transaction is exempt from registration. The undersigned consents to the placing of a legend on its certificate for the Warrant Stock stating that the Warrant Stock has not been registered and
setting forth the restriction on transfer contemplated hereby and to the placing of a stop transfer order on the books of the Company and with any transfer agents against the Warrant Stock until the Warrant Stock may be legally resold or distributed
without restriction. 

 The undersigned has considered the federal and state income tax implications of the exercise
of the Warrant and the purchase and subsequent sale of the Warrant Stock. 
  

			
	 
		
	Dated:	 	
		 	 
		 	

  

 2 

 Schedule of Warrant Holders 
 AGTC Advisors Fund, L.P. 
 Applied Genomic
Technology Capital Fund, L. P. 
 Gilde Europe Food & Agribusiness Fund, B.V. 
 NewcoGen—Elan LLC 
 NewcoGen—Long Reign
Holding LLC 
 NewcoGen—PE LLC 
 NewcoGen Equity Investors LLC 
 Pieter Muntendam 
 ST NewcoGen LLC 
 Stelios Papadopoulos 
  

 3Warrant issued to Silicon Valley Bank, dated November 9, 2007

 Exhibit 4.6 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO
THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN
FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 WARRANT TO PURCHASE STOCK 
 Company: BG Medicine, Inc., a Delaware corporation

 Number of Shares: As set forth below 
 Class of Stock: As set forth below 
 Warrant Price: As set forth below 
 Issue Date: November 9, 2007 
 Expiration
Date: November 9, 2017 
  

			
	 Credit Facility:
	  	This Warrant is issued in connection with that certain Loan and Security Agreement of even date herewith between Silicon Valley Bank and the Company (the “Loan
Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK
(Silicon Valley Bank, together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, is referred to hereinafter as “Holder”) is entitled to purchase the number of fully paid
and nonassessable shares (the “Shares”) of the class of securities (the “Class”) of the above-named company (the “Company”) at the Warrant Price, all as set forth herein and as adjusted pursuant to Article 2
of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. 
 A. Number and
Class of Shares; Warrant Price. 
 (1) Certain Definitions. As used herein, the
following definitions have the respective meanings set forth below: 
 “Common Stock” means the
Company’s common stock, $0.001 par value per share, and any securities of the Company into or for which the outstanding shares of such common stock may be converted, reclassified, reorganized or exchanged. 
 “IPO” means the Company’s initial, underwritten offering and sale of its shares to the public pursuant to an
effective registration statement under the Securities Act of 1933, as amended. 
 “Qualified Financing”
means the first sale or issuance by the Company after the Issue Date of this Warrant set forth above, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to
one or more investors for cash for financing purposes. 

 “Qualified Financing Securities” means the class and
series of convertible preferred stock or other senior equity security sold or issued by the Company in the Qualified Financing. 
 “Qualified Financing Price” means the lowest price per share for which Qualified Financing Securities are sold or issued by the Company in the Qualified Financing. 
 “Series C Price” means $3.65, subject to adjustment from time to time upon the occurrence of events described
in Article 2 hereof. 
 “Series C Stock” shall mean the Company’s Series C
Preferred Stock, $0.001 par value per share, and any securities of the Company into or for which the outstanding shares of Series C Preferred Stock may be converted, reclassified, reorganized or exchanged. 
 (2) Class of Shares. The class and series of the Company’s capital stock (the
“Class”) for which this Warrant shall be exercisable shall initially be Common Stock; provided, that if a Qualified Financing shall occur prior to the consummation of the IPO and (a) the Qualified Financing Price is less than
or equal to the then-effective Warrant Price, then the “Class” shall be Qualified Financing Securities from and after the consummation of such Qualified Financing, or (b) the Qualified Financing Price is greater than the
then-effective Warrant Price, then the “Class” shall be Series C Stock from and after the consummation of such Qualified Financing. 
 (3) Warrant Price. The purchase price per Share hereunder (the “Warrant Price”) shall initially be $7.81, subject to adjustment from time to time in accordance with the
provisions of this Warrant; provided, that if a Qualified Financing shall occur prior to the consummation of the IPO and (a) this Warrant becomes exercisable for Series C Stock in accordance with Paragraph (A)(2) above, the
“Warrant Price” shall be the Series C Price from and after the consummation of such Qualified Financing, or (b) this Warrant becomes exercisable for Qualified Financing Securities, the “Warrant Price” shall be the
Qualified Financing Price from and after the consummation of such Qualified Financing, each such Warrant Price subject to adjustment from time to time in accordance with the provisions of this Warrant. 
 (4) Number of Shares. This Warrant shall be exercisable for the Initial Shares plus the Additional Shares
(if any). 
 (a) Initial Shares. As used herein, “Initial Shares” initially means
25,608 shares of the Class, subject to adjustment from time to time in accordance with the provisions of this Warrant; provided, that if a Qualified Financing shall occur prior to the consummation of the IPO and (a) this Warrant becomes
exercisable for Series C Stock in accordance with Paragraph (A)(2) above, “Initial Shares” shall mean, from and after the consummation of such Qualified Financing, such number of shares of the Class as shall equal
(i) $200,000, divided by (ii) the Series C Price, or (b) this Warrant becomes exercisable for Qualified Financing Securities, “Initial Shares” shall mean, from and after the consummation of such Qualified Financing,
such number of shares of the Class as shall equal (i) $200,000, divided by (ii) the Qualified Financing Price, in any case subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

 

 2 

 (b) Additional Shares. This Warrant shall become
exercisable for the Additional Shares, if at all, on and as of the date (if any) on which Bank (as defined in the Loan Agreement) makes the Second Bridge Loan Advance (as defined in the Loan Agreement) to the Company. As used herein,
“Additional Shares” means such number of additional shares of the Class as shall equal (i) $100,000, divided by (ii) the Warrant Price in effect on and as of the date of such Second Bridge Loan Advance, subject to adjustment
thereafter from time to time in accordance with the provisions of this Warrant. 
 (c) As used herein,
“Shares” means the Initial Shares, plus the Additional Shares (if any), as adjusted from time to time in accordance with the provisions of this Warrant. 
 ARTICLE 1. EXERCISE. 
 1.1 Method of Exercise. Holder
may exercise this Warrant by delivering the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the
conversion right set forth in Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for
the Shares being purchased. 
 1.2 Conversion Right. In lieu of exercising this Warrant as specified in
Article 1.1, Holder may from time to time convert this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise
of this Warrant minus the aggregate Warrant Price of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 
 1.3 Fair Market Value. If the Company’s Common Stock is traded in a public market and the Shares are Common Stock, the fair
market value of a Share shall be the closing price of a share of Common Stock reported for the business day immediately before Holder delivers this Warrant together with its Notice of Exercise to the Company (or in the instance where the Warrant is
exercised immediately prior to the effectiveness of the IPO, the “price to public” per share price specified in the final prospectus relating to such offering). If the Company’s Common Stock is traded in a public market and the Shares
are preferred stock, the fair market value of a Share shall be the closing price of a share of the Company’s Common Stock reported for the business day immediately before Holder delivers this Warrant together with its Notice of Exercise to the
Company (or, in the instance where the Warrant is exercised immediately prior to the effectiveness of the IPO, the initial “price to public” per share price specified in the final prospectus relating to such offering), in both cases,
multiplied by the number of shares of the Company’s Common Stock into which a Share is convertible. If the Company’s Common Stock is not traded in a public market, the Board of Directors of the Company shall determine fair market value in
its reasonable good faith judgment. 
  

 3 

 1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or
converts this Warrant and, if applicable, the Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has
not expired, a new Warrant representing the Shares not so acquired. 
 1.5 Replacement of Warrants. On receipt of
evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to
the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 
 1.6 Treatment of Warrant Upon Acquisition of Company. 
 1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale, license,
or other disposition of all or substantially all of the assets of the Company, or any reorganization, consolidation, merger or sale of outstanding capital stock of the Company where the holders of the Company’s securities before the transaction
beneficially own less than a majority of the outstanding voting securities of the surviving entity after the transaction (but excluding the IPO). 
 1.6.2 Treatment of Warrant at Acquisition. 
 A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition in which the sole consideration is cash, either (a) Holder shall exercise its conversion or purchase right under this Warrant and such
exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall provide the
Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to
Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 
 B) Upon the
written request of the Company, Holder agrees that, in the event of an Acquisition that is an “arms length” sale of all or substantially all of the Company’s assets (and only its assets) to a third party that is not an Affiliate (as
defined below) of the Company (a “True Asset Sale”), either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such
Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue until the Expiration Date if the Company continues as a going concern following the closing of any such True Asset Sale. The Company shall provide the
Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to
Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 
  

 4 

 C) Upon the closing of any Acquisition other than those particularly
described in subsections (A) and (B) above, the successor entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable
upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price and/or number of Shares shall be adjusted accordingly. 
 As used herein “Affiliate” shall mean any person or entity that owns or controls directly or indirectly ten percent (10%) or more of
the stock of Company, any person or entity that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or entity’s officers, directors, joint venturers or partners, as applicable.

 ARTICLE 2. ADJUSTMENTS TO THE SHARES. 
 2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the outstanding shares of the Class payable in Common Stock or other securities after the date hereof, then
upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend
occurred. If the Company subdivides the outstanding shares of the Class after the date hereof by reclassification or otherwise into a greater number of shares or takes any other action after the date hereof which increases the amount of Common
Stock into which the one share of the Class is convertible, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are
combined or consolidated, by reclassification or otherwise, after the date hereof into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 
 2.2 Reclassification, Exchange, Combinations or Substitution. Upon any reclassification, exchange, substitution, or other event
that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and
property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include, without limitation, any automatic conversion of
the outstanding or issuable securities of the Company of the same class or series as the Shares to Common Stock pursuant to the terms of the Company’s Amended and Restated Certificate of Incorporation, as amended and/or restated and
in effect from time to time (the “Certificate”). The Company or its successor shall promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or
conversion of this Warrant as a result of such reclassification, exchange, substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this
Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of
securities or property issuable upon exercise of the new Warrant. The provisions of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 
  

 5 

 2.3 Adjustments for Diluting Issuances. The number of shares of Common Stock
issuable upon conversion of the Shares shall be subject to adjustment, from time to time in the manner set forth in the Certificate as if the Shares were issued and outstanding on and as of the date of any such required adjustment. The anti-dilution
provisions set forth for the Class in the Certificate in effect as of the Issue Date may not be amended, modified or waived, without the prior written consent of Holder unless such amendment, modification or waiver affects the rights
associated with the Shares in the same manner as such amendment, modification or waiver affects the rights associated with all other shares of the Class. 
 2.4 No Impairment. The Company shall not, by amendment of the Certificate or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out of all the provisions of
this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article against impairment. 
 2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of the Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share.
If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by multiplying the fractional interest by the fair market value of
a full Share. 
 2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or
number of Shares, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the
facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price, Class and number of Shares in effect upon the date thereof and the series of adjustments
leading to such Warrant Price, Class and number of Shares. 
 ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

 3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as
follows: 
 (a) The initial Warrant Price referenced on the first page of this Warrant is not greater
than the price per share at which shares of the same class and series as the Shares were last issued in an arms-length transaction in which at least $500,000 of such shares were sold. 
 (b) All Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all
securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or
under applicable federal and state securities laws. 
  

 6 

 (c) The Company’s capitalization table attached hereto as
Schedule 1 is true and complete as of the Issue Date. 
 3.2 Notice of Certain Events. If the Company
proposes at any time (a) to declare any dividend or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription or
sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock; (c) to effect any reclassification, reorganization or recapitalization of any of its
stock; (d) to effect an Acquisition or to liquidate, dissolve or wind up; or (e) offer holders of registration rights the opportunity to participate in an underwritten public offering of the Company’s securities for cash, then, in
connection with each such event, the Company shall give Holder: (1) at least 10 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the
holders of shares of the same class and series as the Shares will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (c) and (d) above; (2) in the case of the matters
referred to in (c) and (d) above at least 10 days prior written notice of the date when the same will take place (and specifying the date on which the holders of shares of the same class and series as the Shares will be entitled
to exchange their shares for the securities or other property deliverable upon the occurrence of such event); and (3) in the case of the matter referred to in (e) above, the same notice as is given to the holders of such registration
rights. 
 3.3 Registration Under Securities Act of 1933, as amended. The Company agrees that the Shares or, if the
Shares are convertible into Common Stock of the Company, such Common Stock, shall have certain incidental, or “Piggyback,” registration rights pursuant to and as set forth in Sections 3 through 11, 13 and 15(b), 15(d) and
15(h) (the “Applicable Sections”) of that certain Third Amended and Restated Investor Rights Agreement dated as of May 1, 2007 among the Company and the other parties named therein, as amended and/or restated and in effect from
time to time (the “Rights Agreement”). The Applicable Sections in effect as of the Issue Date may not be amended, modified or waived without the prior written consent of Holder unless such amendment, modification or waiver affects the
rights associated with the Shares in the same manner as such amendment, modification, or waiver affects the rights associated with all other shares of the Class held by holders who are parties to the Rights Agreement. In addition, pursuant to
Section 5(b) of the Rights Agreement, the Holder agrees that it shall enter into a holdback agreement with the managing underwriters of the Company’s pending IPO for such longer period as the managing underwriters may request
provided that the other conditions of Section 5(b) are satisfied. 
 3.4 No Shareholder Rights. Except as
provided in this Warrant, Holder will not have any rights as a shareholder of the Company until the exercise of this Warrant. 
 3.5 Certain Information. The Company agrees to provide Holder at any time and from time to time with such information as Holder may reasonably request for purposes of Holder’s compliance with regulatory, accounting and
reporting requirements applicable to Holder. 
  

 7 

 ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants to the
Company as follows: 
 4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of
this Warrant by Holder will be acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed
for the specific purpose of acquiring this Warrant or the Shares. 
 4.2 Disclosure of Information. Holder has
received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity
to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or
could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 
 4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has experience as an investor in securities of
companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business matters that
Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling
persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 
 4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act. 
 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise or conversion hereof have not been
registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the
Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are
otherwise available. 
 ARTICLE 5. MISCELLANEOUS. 
 5.1 Term: This Warrant is exercisable in whole or in part at any time and from time to time on or before the Expiration Date. 
  

 8 

 5.2 Legends. This Warrant and the Shares (and the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE ACT, OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 OF THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE
COMPANY TO SILICON VALLEY BANK DATED AS OF NOVEMBER 9, 2007 MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF
LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the
transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an
opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated
under the Act. 
 5.4 Transfer Procedure. After receipt by Silicon Valley Bank (“Bank”) of the executed
Warrant, Bank will transfer all of this Warrant to SVB Financial Group, Holder’s parent company. Subject to the provisions of Article 5.3 and upon providing the Company with written notice, SVB Financial Group and any subsequent Holder
may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection
with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender
this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). The Company may refuse to transfer this Warrant or the Shares to any person who directly competes with the Company, unless, in either case, the stock of
the Company is publicly traded. 
  

 9 

 5.5 Notices. All notices and other communications from the Company to the
Holder, or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or Holder, as the case
may (or on the first business day after transmission by facsimile) be, in writing by the Company or such holder from time to time. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in
connection with a transfer or otherwise: 
 SVB Financial Group 
 Attn: Treasury Department 
 3003 Tasman Drive, HA 200 
 Santa Clara, CA 95054 
 Telephone: 408-654-7400 
 Facsimile: 408-496-2405 
 Notice to the Company shall be addressed as follows
until Holder receives notice of a change in address: 
 BG Medicine, Inc. 
 Attn: Mark Shooman 
 610 Lincoln Street North 
 Waltham, MA 02451 
 Telephone: 781-890-1199 
 Facsimile: 781-895-1119 
 5.6 Waiver. This Warrant and any term hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 
 5.7 Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect
from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 
 5.8 Automatic
Conversion upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Article 1.3 above is greater than the Warrant
Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be converted pursuant to Article 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised
or converted, and the Company shall promptly deliver a certificate representing the Shares (or such other securities) issued upon such conversion to Holder. 
 5.9 Counterparts. This Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement. 
 5.10 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, without giving effect to its principles regarding conflicts of law. 
  

 10 

			
	“COMPANY”
	
	BG MEDICINE, INC.
		
	By:	 	/s/ Mark D. Shooman
	Name:	 	Mark D. Shooman
		 	(Print)
	Title:	 	CFO
	
	“HOLDER”
	
	SILICON VALLEY BANK
		
	By:	 	/s/ Clark Hayes
	Name:	 	Clark Hayes
		 	(Print)
	Title:	 	RM

  

 11 

 APPENDIX 1 
 NOTICE OF EXERCISE 
 1. Holder elects to purchase
                 shares of the Common/Series
                             Preferred [strike one] Stock of
                                     pursuant to the terms of the
attached Warrant, and tenders payment of the purchase price of the shares in full. 
 [or] 
 1. Holder elects to convert the attached Warrant into Shares/cash [strike one] in the manner specified in the Warrant. This conversion
is exercised for
                                         of the
Shares covered by the Warrant. 
 [Strike paragraph that does not apply.] 
 2. Please issue a certificate or certificates representing the Shares in the name specified below: 
  

	
	
	  
	Holders Name
	
	 
	
	  
	(Address)

 3. By its execution below and for the benefit of the Company, Holder hereby
restates each of the representations and warranties in Article 4 of the Warrant as of the date hereof. 
  

			
	HOLDER:
	
	 

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	(Date):	 	 

  

 12 

 SCHEDULE 1 
 Company Capitalization Table 
 See attached 
  

 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]